• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 483204 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1417192803 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1417192803 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Nektar Therapeutics: 52-Week High Recently Eclipsed (NKTR)

Published on Fri, 04/19/2013 - 14:16
By Peter Chu

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded today at $11.34, breaking its 52-week high. So far today approximately 878,000 shares have been exchanged, as compared to an average 30-day volume of 834,000 shares.

Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar Therapeutics share prices have moved between a 52-week high of $11.34 and a 52-week low of $5.65 and are now trading 96% above that low price at $11.06 per share. Over the past week, the 200-day moving average (MA) has gone up 0.6% while the 50-day MA has advanced 1.6%.

There is potential upside of 8.5% for shares of Nektar Therapeutics based on a current price of $11.06 and an average consensus analyst price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $10.03 and subsequent support at its 200-day MA of $8.87.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Clean Energy Fuels Makes a Move: Down 5....

Clean Energy Fuels (NASDAQ:CLNE) is one of today's notable stocks in decline, down 5.0% ...

Target has the Highest Free Cash Flow Pe...

Below are the three companies in the General Merchandise Stores industry with the highe ...

Shares of Manitowoc Under Pressure, Down...

Manitowoc (NYSE:MTW), a company whose shares are moving quickly, is trading 5.1% lower ...

Schweitzer-Mauduit International has the...

Below are the three companies in the Paper Products industry with the highest free cash ...

Buyers Accumulate Shares of Texas Roadho...

Texas Roadhouse (NASDAQ:TXRH) is one of today's biggest movers, up 5.1% to $33.31. The ...

Kirby Ranks the Highest in Terms of Free...

Below are the three companies in the Marine industry with the highest free cash flow pe ...

MarkWest Energy Partners Makes a Move: D...

MarkWest Energy Partners (NYSE:MWE) is one of today's biggest movers, down 5.1% to $70. ...

Amsurg is Among the Companies in the Hea...

Below are the three companies in the Health Care Facilities industry with the highest f ...